Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30149681 | 0.91 | NPSR1 (0.44) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| SCHEMBL31733084 | 0.85 | NPSR1 (0.38) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| SCHEMBL12462298 | 0.80 | NPSR1 (0.46) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| SCHEMBL225044 | 0.80 | NPSR1 (0.46) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| SCHEMBL28849860 | 0.79 | NPSR1 (0.33) | NPSR1CYP4F2CYP4A11LMNA | |
| SCHEMBL30915390 | 0.77 | LMNA (0.35) | NPSR1CYP4F2CYP4A11LMNAALDH1A1 | |
| SCHEMBL2517854 | 0.76 | NPSR1 (0.45) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| SCHEMBL759802 | 0.75 | NPSR1 (0.54) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| SCHEMBL230256 | 0.75 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| SCHEMBL20702573 | 0.73 | FFAR3 (0.38) | MEN1KMT2APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4305037-B1 | KRAS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4305038-B1 | KRAS G12D INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20240317769-A1 | KRAS G12D INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| EP-4305038-A1 | KRAS G12D INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-4305037-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-117242074-A | KRAS G12D inhibitors | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117177976-A | KRAS inhibitors | 百时美施贵宝公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2022192794-A1 | KRAS G12D INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022192790-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022188729-A1 | FUSED RING DERIVATIVES USEFUL AS KRAS G12D INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217982-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | NPSR1 4820/4885CYP4F2 4547/4885CYP4A11 4320/4885 |
| US-20240317769-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | NPSR1 4839/4885CYP4F2 4598/4885CYP4A11 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.